Myxoma Virus Protein M029 Is a Dual Function Immunomodulator that Inhibits PKR and Also Conscripts RHA/DHX9 to Promote Expanded Host Tropism and Viral Replication

PLoS Pathogens

Volumn 9, Issue 7, 2013, Pages

  Rahman, Masmudur M ^a   Liu, Jia ^a   Chan, Winnie M ^a   Rothenburg, Stefan ^b   McFadden, Grant ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

M029 PROTEIN; PROTEIN KINASE R; RNA HELICASE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOPRECIPITATION; LIQUID CHROMATOGRAPHY; MYXOMA VIRUS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RABBIT; REAL TIME POLYMERASE CHAIN REACTION; SCORING SYSTEM; TANDEM MASS SPECTROMETRY; TROPISM; VIRUS INFECTION; VIRUS REPLICATION; WESTERN BLOTTING;

EID: 84884733748     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003465     Document Type: Article

References (66)

1. Perdiguero B, Esteban M, (2009) The interferon system and vaccinia virus evasion mechanisms. J Interferon Cytokine Res 29: 581-598.
2. Seet BT, Johnston JB, Brunetti CR, Barrett JW, Everett H, et al. (2003) Poxviruses and immune evasion. Annu Rev Immunol 21: 377-423.
3. Bahar MW, Graham SC, Chen RA, Cooray S, Smith GL, et al. (2011) How vaccinia virus has evolved to subvert the host immune response. J Struct Biol 175: 127-134.
4. Chang HW, Watson JC, Jacobs BL, (1992) The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase. Proc Natl Acad Sci U S A 89: 4825-4829.
5. Davies MV, Chang HW, Jacobs BL, Kaufman RJ, (1993) The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms. J Virol 67: 1688-1692.
6. Rivas C, Gil J, Melkova Z, Esteban M, Diaz-Guerra M, (1998) Vaccinia virus E3L protein is an inhibitor of the interferon (i.f.n.)-induced 2-5A synthetase enzyme. Virology 243: 406-414.
7. Rice AD, Turner PC, Embury JE, Moldawer LL, Baker HV, et al. (2011) Roles of vaccinia virus genes E3L and K3L and host genes PKR and RNase L during intratracheal infection of C57BL/6 mice. J Virol 85: 550-567.
8. Smith EJ, Marie I, Prakash A, Garcia-Sastre A, Levy DE, (2001) IRF3 and IRF7 phosphorylation in virus-infected cells does not require double-stranded RNA-dependent protein kinase R or Ikappa B kinase but is blocked by Vaccinia virus E3L protein. J Biol Chem 276: 8951-8957.
9. Xiang Y, Condit RC, Vijaysri S, Jacobs B, Williams BR, et al. (2002) Blockade of interferon induction and action by the E3L double-stranded RNA binding proteins of vaccinia virus. J Virol 76: 5251-5259.
10. Myskiw C, Arsenio J, van Bruggen R, Deschambault Y, Cao J, (2009) Vaccinia virus E3 suppresses expression of diverse cytokines through inhibition of the PKR, NF-kappaB, and IRF3 pathways. J Virol 83: 6757-6768.
11. Guerra S, Caceres A, Knobeloch KP, Horak I, Esteban M, (2008) Vaccinia virus E3 protein prevents the antiviral action of ISG15. PLoS Pathog 4: e1000096.
12. Chang HW, Jacobs BL, (1993) Identification of a conserved motif that is necessary for binding of the vaccinia virus E3L gene products to double-stranded RNA. Virology 194: 537-547.
13. Brandt TA, Jacobs BL, (2001) Both carboxy- and amino-terminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model. J Virol 75: 850-856.
14. Brandt T, Heck MC, Vijaysri S, Jentarra GM, Cameron JM, et al. (2005) The N-terminal domain of the vaccinia virus E3L-protein is required for neurovirulence, but not induction of a protective immune response. Virology 333: 263-270.
15. White SD, Jacobs BL, (2012) The amino terminus of the vaccinia virus E3 protein is necessary to inhibit the interferon response. J Virol 86: 5895-5904.
16. Langland JO, Jacobs BL, (2002) The role of the PKR-inhibitory genes, E3L and K3L, in determining vaccinia virus host range. Virology 299: 133-141.
17. Kim YG, Muralinath M, Brandt T, Pearcy M, Hauns K, et al. (2003) A role for Z-DNA binding in vaccinia virus pathogenesis. Proc Natl Acad Sci U S A 100: 6974-6979.
18. Marq JB, Hausmann S, Luban J, Kolakofsky D, Garcin D, (2009) The double-stranded RNA binding domain of the vaccinia virus E3L protein inhibits both RNA- and DNA-induced activation of interferon beta. J Biol Chem 284: 25471-25478.
19. Valentine R, Smith GL, (2010) Inhibition of the RNA polymerase III-mediated dsDNA-sensing pathway of innate immunity by vaccinia virus protein E3. J Gen Virol 91: 2221-2229.
20. Cao H, Dai P, Wang W, Li H, Yuan J, et al. (2012) Innate immune response of human plasmacytoid dendritic cells to poxvirus infection is subverted by vaccinia E3 via its Z-DNA/RNA binding domain. PLoS One 7: e36823.
21. Beattie E, Denzler KL, Tartaglia J, Perkus ME, Paoletti E, et al. (1995) Reversal of the interferon-sensitive phenotype of a vaccinia virus lacking E3L by expression of the reovirus S4 gene. J Virol 69: 499-505.
22. Shors T, Jacobs BL, (1997) Complementation of deletion of the vaccinia virus E3L gene by the Escherichia coli RNase III gene. Virology 227: 77-87.
23. Vijaysri S, Talasela L, Mercer AA, McInnes CJ, Jacobs BL, et al. (2003) The Orf virus E3L homologue is able to complement deletion of the vaccinia virus E3L gene in vitro but not in vivo. Virology 314: 305-314.
24. Guerra S, Abaitua F, Martinez-Sobrido L, Esteban M, Garcia-Sastre A, et al. (2011) Host-range restriction of vaccinia virus E3L deletion mutant can be overcome in vitro, but not in vivo, by expression of the influenza virus NS1 protein. PLoS One 6: e28677.
25. Myskiw C, Arsenio J, Hammett C, van Bruggen R, Deschambault Y, et al. (2011) Comparative analysis of poxvirus orthologues of the vaccinia virus E3 protein: modulation of protein kinase R activity, cytokine responses, and virus pathogenicity. J Virol 85: 12280-12291.
26. Barrett JW, Cao JX, Hota-Mitchell S, McFadden G, (2001) Immunomodulatory proteins of myxoma virus. Semin Immunol 13: 73-84.
27. Chakrabarti S, Sisler JR, Moss B, (1997) Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23: 1094-1097.
28. Johnston JB, Barrett JW, Chang W, Chung CS, Zeng W, et al. (2003) Role of the serine-threonine kinase PAK-1 in myxoma virus replication. J Virol 77: 5877-5888.
29. Barrett JW, Alston LR, Wang F, Stanford MM, Gilbert PA, et al. (2007) Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells. J Neurovirol 13: 549-560.
30. Woo Y, Kelly KJ, Stanford MM, Galanis C, Chun YS, et al. (2008) Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells. Ann Surg Oncol 15: 2329-2335.
31. Correa RJ, Komar M, Tong JG, Sivapragasam M, Rahman MM, et al. (2012) Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity. Gynecol Oncol 125: 441-450.
32. Sypula J, Wang F, Ma Y, Bell J, McFadden G, (2004) Myxoma virus tropism in human tumor cells. Gene Ther Mol Biol 8: 103-114.
33. Lun XQ, Zhou H, Alain T, Sun B, Wang L, et al. (2007) Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res 67: 8818-8827.
34. Stanford MM, Shaban M, Barrett JW, Werden SJ, Gilbert PA, et al. (2008) Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther 16: 52-59.
35. Lun X, Yang W, Alain T, Shi ZQ, Muzik H, et al. (2005) Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res 65: 9982-9990.
36. Wennier ST, Liu J, Li S, Rahman MM, Mona M, et al. (2012) Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer. Mol Ther 20: 759-768.
37. Turner PC, Dilling BP, Prins C, Cresawn SG, Moyer RW, et al. (2007) Vaccinia virus temperature-sensitive mutants in the A28 gene produce non-infectious virions that bind to cells but are defective in entry. Virology 366: 62-72.
38. Zachertowska A, Brewer D, Evans DH, (2006) Characterization of the major capsid proteins of myxoma virus particles using MALDI-TOF mass spectrometry. J Virol Methods 132: 1-12.
39. Yuwen H, Cox JH, Yewdell JW, Bennink JR, Moss B, (1993) Nuclear localization of a double-stranded RNA-binding protein encoded by the vaccinia virus E3L gene. Virology 195: 732-744.
40. Bartee E, McFadden G, (2009) Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-beta. Cytokine 47: 199-205.
41. Sadler AJ, Latchoumanin O, Hawkes D, Mak J, Williams BR, (2009) An antiviral response directed by PKR phosphorylation of the RNA helicase A. PLoS Pathog 5: e1000311.
42. Chang HW, Uribe LH, Jacobs BL, (1995) Rescue of vaccinia virus lacking the E3L gene by mutants of E3L. J Virol 69: 6605-6608.
43. Zhang P, Jacobs BL, Samuel CE, (2008) Loss of protein kinase PKR expression in human HeLa cells complements the vaccinia virus E3L deletion mutant phenotype by restoration of viral protein synthesis. J Virol 82: 840-848.
44. Rothenburg S, Seo EJ, Gibbs JS, Dever TE, Dittmar K, (2009) Rapid evolution of protein kinase PKR alters sensitivity to viral inhibitors. Nat Struct Mol Biol 16: 63-70.
45. Sharp TV, Moonan F, Romashko A, Joshi B, Barber GN, et al. (1998) The vaccinia virus E3L gene product interacts with both the regulatory and the substrate binding regions of PKR: implications for PKR autoregulation. Virology 250: 302-315.
46. Romano PR, Zhang F, Tan SL, Garcia-Barrio MT, Katze MG, et al. (1998) Inhibition of double-stranded RNA-dependent protein kinase PKR by vaccinia virus E3: role of complex formation and the E3 N-terminal domain. Mol Cell Biol 18: 7304-7316.
47. Zhang S, Grosse F, (1997) Domain structure of human nuclear DNA helicase II (RNA helicase A). J Biol Chem 272: 11487-11494.
48. Zhou K, Choe KT, Zaidi Z, Wang Q, Mathews MB, et al. (2003) RNA helicase A interacts with dsDNA and topoisomerase IIalpha. Nucleic Acids Res 31: 2253-2260.
49. Fuller-Pace FV, (2006) DExD/H box RNA helicases: multifunctional proteins with important roles in transcriptional regulation. Nucleic Acids Res 34: 4206-4215.
50. Isken O, Baroth M, Grassmann CW, Weinlich S, Ostareck DH, et al. (2007) Nuclear factors are involved in hepatitis C virus RNA replication. RNA 13: 1675-1692.
51. Lawrence P, Rieder E, (2009) Identification of RNA helicase A as a new host factor in the replication cycle of foot-and-mouth disease virus. J Virol 83: 11356-11366.
52. Bolinger C, Sharma A, Singh D, Yu L, Boris-Lawrie K, (2010) RNA helicase A modulates translation of HIV-1 and infectivity of progeny virions. Nucleic Acids Res 38: 1686-1696.
53. Lin L, Li Y, Pyo HM, Lu X, Raman SN, et al. (2012) Identification of RNA helicase A as a cellular factor that interacts with influenza A virus NS1 protein and its role in the virus life cycle. J Virol 86: 1942-1954.
54. Roy BB, Hu J, Guo X, Russell RS, Guo F, et al. (2006) Association of RNA helicase a with human immunodeficiency virus type 1 particles. J Biol Chem 281: 12625-12635.
55. Zhang Z, Yuan B, Lu N, Facchinetti V, Liu YJ, (2011) DHX9 pairs with IPS-1 to sense double-stranded RNA in myeloid dendritic cells. J Immunol 187: 4501-4508.
56. Zhang L, Villa NY, Rahman MM, Smallwood S, Shattuck D, et al. (2009) Analysis of vaccinia virus-host protein-protein interactions: validations of yeast two-hybrid screenings. J Proteome Res 8: 4311-4318.
57. Lalani AS, Graham K, Mossman K, Rajarathnam K, Clark-Lewis I, et al. (1997) The purified myxoma virus gamma interferon receptor homolog M-T7 interacts with the heparin-binding domains of chemokines. J Virol 71: 4356-4363.
58. Alejo A, Ruiz-Arguello MB, Ho Y, Smith VP, Saraiva M, et al. (2006) A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus. Proc Natl Acad Sci U S A 103: 5995-6000.
59. Werden SJ, Lanchbury J, Shattuck D, Neff C, Dufford M, et al. (2009) The myxoma virus m-t5 ankyrin repeat host range protein is a novel adaptor that coordinately links the cellular signaling pathways mediated by Akt and Skp1 in virus-infected cells. J Virol 83: 12068-12083.
60. Rahman MM, Mohamed MR, Kim M, Smallwood S, McFadden G, (2009) Co-regulation of NF-kappaB and inflammasome-mediated inflammatory responses by myxoma virus pyrin domain-containing protein M013. PLoS Pathog 5: e1000635.
61. Mossman K, Nation P, Macen J, Garbutt M, Lucas A, et al. (1996) Myxoma virus M-T7, a secreted homolog of the interferon-gamma receptor, is a critical virulence factor for the development of myxomatosis in European rabbits. Virology 215: 17-30.
62. Nash P, Barry M, Seet BT, Veugelers K, Hota S, et al. (2000) Post-translational modification of the myxoma-virus anti-inflammatory serpin SERP-1 by a virally encoded sialyltransferase. Biochem J 347: 375-382.
63. Barrett JW, Sypula J, Wang F, Alston LR, Shao Z, et al. (2007) M135R is a novel cell surface virulence factor of myxoma virus. J Virol 81: 106-114.
64. Rahman MM, McFadden G, (2011) Myxoma virus lacking the pyrin-like protein M013 is sensed in human myeloid cells by both NLRP3 and multiple Toll-like receptors, which independently activate the inflammasome and NF-kappaB innate response pathways. J Virol 85: 12505-12517.
65. Mohamed MR, Rahman MM, Rice A, Moyer RW, Werden SJ, et al. (2009) Cowpox virus expresses a novel ankyrin repeat NF-kappaB inhibitor that controls inflammatory cell influx into virus-infected tissues and is critical for virus pathogenesis. J Virol 83: 9223-9236.
66. Liu J, Wennier S, Zhang L, McFadden G, (2011) M062 is a host range factor essential for myxoma virus pathogenesis and functions as an antagonist of host SAMD9 in human cells. J Virol 85: 3270-3282.